New research by scientists at the University of Liverpool looks at how artificial intelligence (AI) can help doctors make ...

People want to know more about UpScrolled App and it's owner, Issam Hijazi, after TikTok users leave the platform for the new app.

The ongoing conflict in Gaza has resulted in an alarming death toll, with estimates suggesting as many as 680,000 casualties, ...

Users can note which content they would like to view more frequently. Instagram is handing users some control in deciding what content they see. The social media giant is allowing users to have a say ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

School of Physics and Optoelectronics, Xiangtan University, Xiangtan, Hunan, China Accurate reconstruction of optical fiber curves has important applications in fields like medicine, aerospace, and ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Follow 24/7 Wall St. on Google By Joey Frenette Published ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...